SOSalfo Ouedraogo

Salfo Ouedraogo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Salfo Ouedraogo has a total of 59 co-authors. Here are the top co-authors by number of shared publications:

  • Tata Kadiatou Traore

    Research and Development Laboratory for Phytomedicines and Drugs (LR-D/PM), Institute for Research in Health Sciences (IRSS/CNRST), Ouagadougou, Burkina Faso

    6 shared publications
  • Boladé Constantin Atchade

    Laboratory for Drug Development (LADME), Center for Training, Research and Expertise in Drug Sciences (CEA-CFOREM), Doctoral School of Health Sciences (ED2S), Joseph KI-ZERBO University, BP-7021, Burkina Faso. Phytomedicine and Drug Research and Development Laboratory (LR-D/PM), Health Sciences Research Institute (IRSS), National Center for Scientific and Technological Research (CNRST) BP 7047 Ouagadougou 03, Burkina Faso

    5 shared publications
  • Rasmané Semdé

    Centre de Formation, de Recherche et d’Expertises en sciences du médicament (CEA-CFOREM), Université Joseph KI-ZERBO, Ouagadougou, Burkina Faso

    5 shared publications
  • Sylvin Ouedraogo

    Département Médecine et Pharmacopée Traditionnelles – Pharmacie (MEPHATRA-PH), Institut de Recherche en Sciences de la Santé/Centre National de la Recherche Scientifique et Technologique (IRSS/CNRST), Ouagadougou, Burkina Faso

    4 shared publications
  • Florent Wendinmi Bertrand Goumbri

    Research and Development Laboratory for Phytomedicines and Drugs (LR-D/PM), Institute for Research in Health Sciences (IRSS/CNRST), Ouagadougou, Burkina Faso

    2 shared publications
  • Noufou Ouedraogo

    Laboratoire du Développement des Medicaments (LADME), Ecole Doctorale de la Sante, Université Joseph Ki-Zerbo, 03 BP 7021 Ouaga 03, Burkina Faso

    2 shared publications

Latest Publications

  • Therapeutic Potential of Ampelocissus africana (Lour.) Merr. (Vitaceae) Underutilised and Indigenous Vegetables: Merging Traditional and Scientific Knowledge

    by Boladé Constantin Atchade, Salfo Ouedraogo, Tata Kadiatou Traore, Isanorelle Bonou-Selegbe, Leila Esther Belem-Kabre, Rasmané Semde

    Background: Ampelocissus africana is a plant widely distributed in Africa. A. africana is used in food through its rhizomes and fruits, but also in traditional medicine for its ability to cure a wide range of human diseases. Aim: This review provides an overview of traditional, phytochemical, pharmacological, toxicological, and galenic knowledge regarding the use of A. africana. Methods: Online databases such as Google Scholar, PubMed, ScienceDirect, and African Journals Online (AJOL) were used to identify relevant research on the plant. ChemDraw Professional 15.0® was used to generate the chemical structure of the compounds present in the different parts of the plant. Results:: Ampelocissus africana has demonstrated therapeutic potential through pharmacological testing in several pathologies such as malaria, bacterial/fungal infections, benign prostatic hyperplasia, dermatoses, diseases with inflammatory components, diabetes, and sickle cell disease. Different classes of bioactive compounds have been identified, isolated, and quantified. Eight compounds were isolated from the rhizomes and leaves: β-sitosterol, betulin, 15-hydroxymethyl-16-methylheptadecyl ferulate, 3-hydroxymethyl-5-methyl-16-oxoheptadecyl ferulate, luteolin, derivatives of isorhamnetin and quercetin, and 1-O-β-D-rhamnopyranosyl-4-ethylphenylbut-2-one. Experimental studies have shown that Ampelocissus africana possesses significant anti-inflammatory, antioxidant, anxiolytic, antimalarial, antifungal, antisickling, haemolytic and anti-benign prostatic hyperplasia activity in both in vitro and in vivo models. Toxicological studies on the extracts have proven their safety. The rhizome powder of this plant is used as an excipient in the manufacture of tablets. Conclusion: This literature review provides a solid scientific foundation to guide future research on A. africana Major Findings: Ampelocissus africana exhibits a range of pharmacological activities, primarily attributed to the presence of various molecules belonging to the terpene, sterol and phenolic compound classes. However, further research is needed to better understand its effects, confirm its therapeutic value and accurately assess any potential risks associated with its use.

  • Open Access

    Physicochemical and microbiological characteristics of Calotropis procera Ait. root bark powders from 20 sites in Burkina Faso for standardization

    by Salfo Ouedraogo, Tata Kadiatou Traore, Manegrebem Adele Ouedraogo, Souleymane Compaore, Axelle Astrid Lofo, Boukari Kabore, Rene Dofini Magnini, Mathieu Nitiema, Moumouni Koala, Lazare Belemnaba, et al.

    Calotropis procera is a component of the phytomedicine FACA®, used to manage sickle cell disease in Burkina Faso. This work aimed to standardize plant powders by evaluating the physicochemical characteristics and microbial quality of Calotropis procera root bark powders from different sites, with properties similar to those of the reference harvest site, to optimize the production of the phytomedicine. The samples were collected from different geographical areas of Burkina Faso during the dry season. The population, physicochemical characteristics, and microbial quality of each powder were evaluated. Twenty (20) geolocated harvest sites were identified with various soil types (clay, silt, gravel, and sand). The availability of Calotropis procera was high in Ziniaré, Ouaga 1, and Boromo; average across 8 sites; and low across 9. Physicochemical analyses of the powders revealed general uniformity in pH and residual moisture content. However, differences were observed in color, bitterness, and hygroscopicity. Total phenolics could serve as tracers, given their content is comparable to that of the reference. All samples complied with the specifications of the European Pharmacopeia 11th edition for total aerobic bacteria, yeasts and molds, and E. coli. Pathogens such as Salmonella and Staphylococcus aureus have been found in some powders. This study identified the optimal sites for collecting Calotropis procera samples. Keywords: Sickle cell disease; Calotropis procera; root bark; geographical variability.

  • Open Access

    Development of Lozenges from Fruit Extract of Balanites aegyptiaca (L) Delile (Zygophyllaceae) for the Treatment of Occasional Constipation

    by Ouedraogo Salfo, Traore Kadiatou, Boly Laurent, Tapsoba Carine, Millogo Olivia, Atchade Constantin, Kabore Donacienne, Traore Safiatou, Goumbri Florent, Traore Aristide, et al.

    Balanites aegyptiaca (L.) Del. is a plant whose fruit pulp is traditionally used to treat constipation. They possess inherent laxative properties. This study aimed to improve upon the traditional method of use by developing lozenges with these laxative properties. An infusion was performed, and the physicochemical characteristics of the lyophilized extract were determined. The lozenges were formulated from the extract, and their quality and laxative efficacy in vivo were controlled in NMRI strain mice. The extract was yellow, had a bitter-sweet taste, a characteristic smell, and a fine texture. The pH was 5.56, and the RMC was 1.16%. The powder was highly hygroscopic, and the extraction yield was 33.71%, with a saponoside content of 2.76 μgED/mg. Fifteen (15) formulations were prepared, and formulation F7 was selected for the incorporation of the extract. The F7 was yellow, sweet, with an uncharacteristic odor and a hard appearance. The lozenges were uniform (1.95±0.04 g), with an average pH of 5.85±0.07 and a saponoside content of 2.01±0.26 μgED/mg. The lozenges had an accelerated intestinal transit percentage of 75.74±3.22%, comparable to that of the extract (78.10±4.32%) and castor oil (81.84±9.46%). After slowing down transit with loperamide (45.24±2.38%), the lozenges (60.84±7.13%) brought the percentage close to normal transit (65.94±3.33%). This study highlighted the laxative efficacy of lozenges made from Balanites aegyptiaca fruit pulp extract.

  • Open Access

    Formulation and In Vitro Release Studies of Emulgels Containing Shea Butter and Diclofenac Diethylamine

    by Hermine Zime Diawara, Hyacinthe W. Bonkougou, Charles B. Sombie, Salfo Ouedraogo, Luc Zongo, Josias B. G. Yameogo, Rasmané Semde

    Shea butter is a raw material widely used in cosmetology. Its use in the pharmaceutical sector is becoming increasingly popular. As it’s commonly produced in Burkina Faso, it can help reduce medicine costs. Several dermatological formulations (creams, body milks, ointments) have been developed in our laboratories in Burkina Faso. However, some active ingredients are not compatible with those bases due to their hydrophilic-lipophilic balance. The emulgel form can thus be a solution. Moreover, this type of dermatological base has not yet been reported in the literature on shea butter. The main objective of our study was to develop an emulgel based on shea butter, and diclofenac diethylamine was chosen as the active ingredient. Emulgel formulations were prepared with shea butter, carbomer 980, or arabic gum and diclofenac diethylamine. Physical quality control was performed against the Diclofenac Reference emulgel. The better emulgel formulations were tested for in vitro release of diclofenac diethylamine, compared with the Diclofenac Reference emulgel. The formulated emulgel was homogeneous, whitish in colour. The pH ranged from 6.53 to 6.71. The emulgel made with 0.5% carbomer 980 had a viscosity close to that of the Diclofenac Reference emulgel. Their diclofenac diethylamine content conformed to standards (99.47% and 100.55%). The release rate of these formulations after 6 hours ranged from 58.66% to 66.26%. The diclofenac reference emulgel had a lower rate of 44.02%. Locally produced shea butter can thus be used to formulate an emulgel incorporating diclofenac diethylamine as the active ingredient. Keywords: Diclofenac diethylamine, emulgel, shea butter, carbomer, arabic gum.

  • Open Access

    FORMULATION AND CHARACTERIZATION OF EFFERVESCENT TABLETS FROM A TRADITIONAL MEDICINE RECIPE FOR DENTAL CARE

    by Bolade Constantin Atchade, Salfo Ouedraogo, Tata Kadiatou Traore, Isanorelle Bonou-Selegbe, Rasmane Semde

    Objective: Plant use to treat pathologies is increasingly common in Africa. Our study focuses on a recipe (active ingredient) of traditional medicine that has proven itself in treating dental caries and oral pathologies. This study aims to formulate and evaluate the quality of effervescent tablets based on the recipe (active ingredient) for treating dental caries and oral hygiene. Methods: A physicochemical and pharmacotechnical characterization of the recipe (RMC, pH, Hausner index, Carr index, flow rate) was carried out. Five stoichiometric ratios of the citric acid/sodium bicarbonate combination were used (1:3.32; 1:3.11; 1:3; 1:2.93; 1:2.87). The tablets were obtained after wet granulation. Pharmacotechnical tests were carried out according to the European Pharmacopoeia 10th Ed to determine the most optimal formulation that could promote rapid release of the active ingredient. Results: The recipe constituting the active ingredient has properties with an apparent density of 0.50, and a density after tamping of 0.65. The compressibility index is 23.61, and the Hausner index is 1.30. These fairly weak rheological properties required improvement through granulation. A total of 5 formulations were obtained. Formulations F2 to F5 had a disintegration time of less than 5 min. The friability rate was less than 4.60%, 0.86%, 0.91%, 0.75%, and 1.22 for the formulations respectively F1 to F5 and the hardness 95N, 81.8N, 118N, 103.6N, 89.8N. The stoichiometric ratio of 1:3.11 gave us the most optimal formulation with a disintegration time of 156 seconds, a friability rate of 0.86%, and a pH of 5.13. Conclusion: These results demonstrate the feasibility of a solid form to be redispersed for use in oral hygiene.


  • Open Access

    Evaluation of toxicity, antispasmodic, and analgesic activities of Improved Traditional Medicine (ITM) based on Diospyros mespiliformis and Combretum micranthum indicated in the treatment of gastrointestinal disorders

    by Tata Kadiatou Traore, Boladé Constantin Atchade, Salfo Ouedraogo, Oumarou Noura Maman, Benjamin Ouedraogo, Gniré Zalikatou Gounou, Dado Jean Noël Kousse, René Sawadogo, Noufou Ouedraogo

    This study focused on an improved traditional herbal medicine (ITHM) used in capsule form for the treatment of gastrointestinal disorders. This study aimed to investigate the phytochemistry, toxicity, and pharmacological activity of the ITM. ITM and extracts underwent phytochemical characterization tests and their dosages. Antioxidant, antispasmodic and analgesic properties and acute toxicity study were realized. Bioactive compounds, including flavonoids, saponins, tannins, etc. were detected. The total phenolic of the ITM were higher with 109.02±0.15 mg EAT/g. The highest total flavonoid content was obtained by the decocted with 17.04±0.25 mg EQ/g and ITM with 16.91± 0.80 mg EQ/g. ITM had the best antioxidant activity by the DPPH method with an IC50 of 24.65 ± 1.05 µg/ml; the decocted had the best activity by the ABTS method with an IC50 of 12.86 ± 0.95 µg/ml and the extracts and ITM had significantly the same activities by LPO method, hence the choice of ITM for the rest of the pharmacological activity. ITM has a low toxicity and an estimated LD50 of 5000 mg/kg. The maximum antispasmodic effect of ITM at the maximum concentration of 3.98 mg/mL was 87.30% with an effective concentration 50 (EC50) of 0.66±0.05 mg/mL. The analgesic effect of ITM was dose-dependent, with inhibition percentages at the dose of 50 mg/kg of 59.82%, that of 100 mg/kg of 64.73% and that of 150 mg/kg of 71.43%. The results on ITM provide a scientific basis for its use in the management of gastric pathologies. Keywords: ITM; Phytochemicals; Antioxidants; Acute toxicity; Antispasmodic; Analgesic.

  • Open Access

    Formulation of Functional Food Supplements: Case Study of Manufacturing Process Optimization at ‘Sarepta Production’, Burkina Faso

    by Mimtiri S. Zongo, Aline F. Tiendrebeogo, Davy P-W Bembamba, Yilédoma T. M. Lengane, Wilfried F.P. Traore, Lucien Kabore, Heiko Lange, Rosemary R. Canfua, Salfo Ouedraogo, Modeste W. Ouedraogo, et al.

    Introduction: In the context of promoting local resources and achieving food sovereignty, plant-based food supplements play a key role. However, their production often remains artisanal, making them prone to contamination and quality inconsistency. Objective: This study aimed to harmonize and standardize the manufacturing practices of four dietary supplements produced at the “Sarepta Production” unit in Ouagadougou, Burkina Faso, by integrating Good Manufacturing Practices (GMP) and Good Hygiene Practices (GHP). Methodology: Standard Operating Procedures (SOPs) were developed for each stage of the production process. Microbiological analyses were carried out on three successive batches at Agence Nationale pour la Sécurité Sanitaire de l’Environnement, de l’Alimentation, du Travail et des produits de santé (ANSSEAT) using standards established by the International Organization for Standardization (ISO standards) to assess sanitary quality. Results and Discussion: The results showed a progressive reduction in total aerobic mesophilic flora, yeasts, molds, and thermotolerant coliforms across the three production cycles. No pathogenic microorganisms like Salmonella, E. coli, or S. aureus were detected. The implementation of GMP, GHP, and Hazard Analysis and Critical Control Points (HACCP) principles enabled effective control of critical points, such as raw material reception, mixing, packaging, and storage. Conclusion: This study demonstrates that strict integration of hygiene and quality standards within small-scale food supplement manufacturing units significantly improves microbiological safety and consumer acceptability. It offers a reproducible model for other local food initiatives in sub-Saharan Africa in general and in Burkina Faso in particular. Keywords: Food Supplements, Good Manufacturing Practices, Microbiological Quality, Harmonization, Local Production, Critical Control Points.

  • Open Access

    Formulation of Effervescent Granules Based on Calotropis procera Ait Powder (Apocynaceae) and Zanthoxylum zanthoxyloides Lam (Rutaceae)

    by Ouédraogo Salfo, Atchadé Constantin, Traoré Kadiatou, Rouamba Martin, Traoré Safiatou, Goumbri Florent, Yaméogo Josias, Ouédraogo Sylvin, Semdé Rasmané

    Introduction: Sickle cell disease is a genetic disease that affects nearly 5% of the world's population and is particularly prevalent in sub-Saharan Africa. The inaccessibility of modern treatment has led to the development of a phytomedicine called FACA® in Burkina Faso. It is formulated in capsule form and contains a mixture of powdered root barks of Zanthoxylum zanthoxyloides and Calotropis procera . This study aims to propose an alternative, easier-to-administer form for patients who have difficulty swallowing capsules by developing effervescent granules. Materials and methods: Pre-formulation studies focused on analyzing the physicochemical and pharmaco-technical properties of the powder mixture. These included macroscopic and organoleptic aspects, pH, residual moisture content, hygroscopicity, granulometry, and flow. Effervescent granules were formulated and manufactured by the wet granulation method. Five formulations (F1-F5) were produced. Citric acid and sodium bicarbonate were used as effervescent vehicles at a ratio of 1:1.25. PVP was used as a binding agent, sucrose as a sweetener, and cornstarch as a diluent. The granulation liquid was distilled water. The granules produced were evaluated for their physicochemical properties and disintegration time. Results and discussion: the results of the physicochemical and pharmaco-technical characteristics guided the choice of excipients and the manufacturing process. The formulations were beige in color and granular in appearance. THR values were <10%, pH ranged from 5.20 ± 0.29 to 5.91 ± 0.17. They were more or less hygroscopic and presented good rheological properties with an effervescence time satisfying the specifications of the European Pharmacopoeia 11th edition. Conclusion: F4 formulation had the best characteristics and could serve as an alternative to capsules. Indeed, being dispersed in water before administration, these granules could be well tolerated by the gastrointestinal tract and promote a more rapid action of the drug at a time of crisis.

  • Open Access

    Impacts of SAYE PLUS , an Antimalarial Phytomedicine With Potential Anti‐COVID‐19, on the Physical, Biological, and Genotoxicity Parameters of Rodents in Short‐Term Toxicity Studies

    by Joël Ouédraogo, Sylvain Ilboudo, Geoffroy Gueswindé Ouédraogo, Virginie Dakuyo, Salfo Ouédraogo, Gaétan D. Somda, Jean Claude Romaric Pingdwindé Ouédraogo, Moussa Ouédraogo, Rasmané Semdé, Sylvin Ouédraogo

    In response to the COVID‐19 pandemic and following the World Health Organization’s call for action, several traditional medicine recipes were used without any scientific prerequisites concerning their safety. The current study investigated several short‐term toxicity parameters of SAYE PLUS, an antimalarial phytomedicine used in COVID‐19 patients in Burkina Faso. Following the guidelines of the Organisation for Economic Co‐operation and Development (OECD), the safety profile of SAYE PLUS was investigated in a battery of tests in rats and mice. In an acute toxicity study, male and female rats received a single oral dose of 2000 mg/kg b.w. of the test substance. For the subacute toxicity test, male and female rats received daily oral doses of 250, 500, and 1000 mg/kg b.w. for 28 days. Acute and subacute toxicity tests were accompanied by food and water intake, body and organ relative weight, and blood chemistry of animals recording. In mutagenicity, sperm quality, and lipid peroxidation tests, mice were orally exposed to daily oral doses of 500, 1000, and 2000 mg/kg for seven days. Single dose of 2000 mg/kg b.w. of SAYE PLUS did not cause rats mortality. The LD 50 is more than 2000 mg/kg b.w. Daily administration of SAYE PLUS for 28 days did not induce any significant change in the water or food intake and the body or organ relative weights of animals. Furthermore, no significant change was observed in biochemical parameters. In the test conditions, the recipe did not induce an increase of micronucleus or changes in sperm motility and number. However, all tested doses of SAYE PLUS induced a significant increase in MDA levels in mice serum. These results show that SAYE PLUS did not induce negative impacts on studied parameters, but the possible lipidic peroxidation observed must be further investigated for its mechanism and effects.


  • Open Access

    COMPARATIVE ASSESSMENT OF THE QUALITY OF PARKIA BIGLOBOSA TRUNK BARK POWDERS JACQ. BENTH (FABACEAE-MIMOSOIDEAE) INTENDED FOR THE PHARMACEUTICAL PRODUCTION OF PHYTO-DRUGS

    by Salfo Ouedraogo, Tata Kadiatou Traore, Bolade Constantin Atchade, Noufou Ouedraogo, Rasmane Semde

    Objective: This study was conducted to determine the physicochemical characteristics and organic and inorganic contaminants of Parkia biglobosa trunk bark powders collected in four localities (Gonse, Yako, Bobo and Nobere) of Burkina Faso. Methods: The parameters studied were the physicochemical characters, the contents of heavy metals, pesticides and the microbial quality according to the methods of the European Pharmacopoeia. Results: The study of these parameters revealed a residual moisture content of less than 10% and a uniform pH, macroscopical character and particle sizes for all raw materials. Total ash ranged from 0.09 to 0.96 for powders from Yako and Bobo, respectively. Contaminant assessment revealed that Parkia biglobosa trunk bark contains high levels of manganese (Mn) and lead (Pb). The microbial analysis shows that the trunk bark powders from Gonse, Yako and Bobo complied with the specifications of the European Pharmacopoeia. Conclusion: These quality control studies allowed the correct identification, characterization and determination of the appropriate harvesting sites for pharmaceutical production of phytomedicine.